Collegium Pharmaceutical (COLL) reported $181.95 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 21.5%. EPS of $1.77 for the same period compares to ...
UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...